argenx SE

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell argenx SE and other ETFs, options, and stocks.

About ARGX

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. 

CEO
Tim van Hauwermeiren
CEOTim van Hauwermeiren
Employees
1,599
Employees1,599
Headquarters
Amsterdam, Noord-Holland
HeadquartersAmsterdam, Noord-Holland
Founded
2008
Founded2008
Employees
1,599
Employees1,599

ARGX Key Statistics

Market cap
53.31B
Market cap53.31B
Price-Earnings ratio
40.00
Price-Earnings ratio40.00
Dividend yield
Dividend yield
Average volume
334.74K
Average volume334.74K
High today
$878.06
High today$878.06
Low today
$859.24
Low today$859.24
Open price
$866.33
Open price$866.33
Volume
303.69K
Volume303.69K
52 Week high
$934.62
52 Week high$934.62
52 Week low
$510.06
52 Week low$510.06

Stock Snapshot

With a market cap of 53.31B, argenx SE(ARGX) trades at $862.20. The stock has a price-to-earnings ratio of 40.00.

On 2025-12-18, argenx SE(ARGX) stock traded between a low of $859.24 and a high of $878.06. Shares are currently priced at $862.20, which is +0.3% above the low and -1.8% below the high.

The argenx SE(ARGX)'s current trading volume is 303.69K, compared to an average daily volume of 334.74K.

During the past year, argenx SE(ARGX) stock moved between $510.06 at its lowest and $934.62 at its peak.

During the past year, argenx SE(ARGX) stock moved between $510.06 at its lowest and $934.62 at its peak.

ARGX News

TipRanks 15h
Argenx Moves Ahead With Its Phase 2 Study on ARGX-119 for Pediatric SMA

Argenx (ARGX) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...

Benzinga 3d
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

Argenx SE (NASDAQ:ARGX) on Monday announced it would discontinue the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and...

TipRanks 4d
Argenx’s Efgartigimod Study: A New Horizon in CIDP Treatment

Argenx (ARGX) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and...

Analyst ratings

89%

of 28 ratings
Buy
89.3%
Hold
7.1%
Sell
3.6%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.